Compass Therapeutics Says FDA Recommended Survival Benefit Trial Before Tovecimig Approval Filing In Biliary Tract Cancer; Company Says New Trial Not Warranted

뉴스 본문을 불러오고 있어요.

Compass Therapeutics Says FDA Recommended Survival Benefit Trial Before Tovecimig Approval Filing In Biliary Tract Cancer; Company Says New Trial Not Warranted | 웨이프 WAPE

Compass Therapeutics Says FDA Recommended Survival Benefit Trial Before Tovecimig Approval Filing In Biliary Tract Cancer; Company Says New Trial Not Warranted

기사 요약

관련 종목

댓글 —